Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments - PubMed (original) (raw)
Review
Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments
Ngolela E Babady et al. Mol Genet Metab. 2007 Sep-Oct.
Abstract
On November 9-12, 2006, the Friedreich's Ataxia Research Alliance (FARA) and the National Institutes of Health (NIH) hosted the Third International Friedreich's Ataxia (FRDA) Scientific Conference at the NIH in Bethesda, Maryland, highlighting the exciting research leading now to a variety of clinical trials that show promise of effective treatments for this devastating disorder. Nearly 150 leading FRDA scientists from around the world discussed their new insights and findings. The presence of six pharmaceutical and biotechnology companies underscored the importance of the public-private partnership that has grown in the past years. Some of these companies are already involved in advancing promising drug compounds into clinical trials, while others are eager to help take newer discoveries through drug development and into subsequent clinical trials. National Institute of Neurological Disorders and Stroke (NINDS) Director Dr. Story Landis noted in her opening remarks for the conference that there was a "palpable sense of energy, excitement, and enthusiasm" over the scientific progress made since the FRDA gene was discovered over 10 years ago.
Similar articles
- [Friedreich's ataxia: recent developments and prospects for treatment].
Legros B, Manto MU. Legros B, et al. Rev Med Brux. 1999 Apr;20(2):73-9. Rev Med Brux. 1999. PMID: 10335100 Review. French. - Common data elements for clinical research in Friedreich's ataxia.
Lynch DR, Pandolfo M, Schulz JB, Perlman S, Delatycki MB, Payne RM, Shaddy R, Fischbeck KH, Farmer J, Kantor P, Raman SV, Hunegs L, Odenkirchen J, Miller K, Kaufmann P. Lynch DR, et al. Mov Disord. 2013 Feb;28(2):190-5. doi: 10.1002/mds.25201. Epub 2012 Dec 12. Mov Disord. 2013. PMID: 23239403 Free PMC article. - Management and therapy for cardiomyopathy in Friedreich's ataxia.
Lynch DR, Regner SR, Schadt KA, Friedman LS, Lin KY, St John Sutton MG. Lynch DR, et al. Expert Rev Cardiovasc Ther. 2012 Jun;10(6):767-77. doi: 10.1586/erc.12.57. Expert Rev Cardiovasc Ther. 2012. PMID: 22894632 Review. - Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.
Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M, Nanetti L, Arpa J, Sanz-Gallego I, Durr A, Charles P, Boesch S, Nachbauer W, Klopstock T, Karin I, Depondt C, vom Hagen JM, Schöls L, Giordano IA, Klockgether T, Bürk K, Pandolfo M, Schulz JB. Reetz K, et al. Lancet Neurol. 2015 Feb;14(2):174-82. doi: 10.1016/S1474-4422(14)70321-7. Epub 2015 Jan 5. Lancet Neurol. 2015. PMID: 25566998 Clinical Trial. - Emerging therapies in Friedreich's ataxia.
Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA. Aranca TV, et al. Neurodegener Dis Manag. 2016;6(1):49-65. doi: 10.2217/nmt.15.73. Neurodegener Dis Manag. 2016. PMID: 26782317 Free PMC article. Review.
Cited by
- Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions.
Lynch DR, Farmer G. Lynch DR, et al. Neuronal Signal. 2021 May 17;5(2):NS20200093. doi: 10.1042/NS20200093. eCollection 2021 Jun. Neuronal Signal. 2021. PMID: 34046211 Free PMC article. Review. - An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models.
Gérard C, Xiao X, Filali M, Coulombe Z, Arsenault M, Couet J, Li J, Drolet MC, Chapdelaine P, Chikh A, Tremblay JP. Gérard C, et al. Mol Ther Methods Clin Dev. 2014 Oct 8;1:14044. doi: 10.1038/mtm.2014.44. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015982 Free PMC article. - Evaluating the progression of Friedreich ataxia and its treatment.
Delatycki MB. Delatycki MB. J Neurol. 2009 Mar;256 Suppl 1:36-41. doi: 10.1007/s00415-009-1007-y. J Neurol. 2009. PMID: 19283349 Review. - Friedreich's ataxia: clinical features, pathogenesis and management.
Cook A, Giunti P. Cook A, et al. Br Med Bull. 2017 Dec 1;124(1):19-30. doi: 10.1093/bmb/ldx034. Br Med Bull. 2017. PMID: 29053830 Free PMC article. Review. - Pharmacotherapy for Friedreich ataxia.
Tsou AY, Friedman LS, Wilson RB, Lynch DR. Tsou AY, et al. CNS Drugs. 2009;23(3):213-23. doi: 10.2165/00023210-200923030-00003. CNS Drugs. 2009. PMID: 19320530 Review.
References
- Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271:1423–1427. - PubMed
- Napierala M, Dere R, Vetcher A, Wells RD. Structure-dependent recombination hot spot activity of GAA.TTC sequences from intron 1 of the Friedreich’s ataxia gene. J Biol Chem. 2004;279:6444–6454. - PubMed
- Son LS, Bacolla A, Wells RD. Sticky DNA: in vivo formation in E. coli and in vitro association of long GAA*TTC tracts to generate two independent supercoiled domains. J Mol Biol. 2006;360:267–284. - PubMed
- Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature. 2003;422:909–913. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous